Navigation Links
Penn Dental Medicine, CHOP Team Show HIV/AIDS Drugs Interfere with Brain's 'Insulation'
Date:1/18/2016

PHILADELPHIA, Jan. 18 2016 /PRNewswire/ -- Antiretroviral therapies (ART) have enabled people with HIV/AIDS to live much longer lives, essentially transforming the disease into a chronic condition. Yet concerns for these patients remain. Up to half of people with HIV on these drug regimens have some sort of cognitive impairment, such as memory loss or problems with executive functioning, despite the virus being almost undetectable in their bodies.

In a new study, researchers from Penn Dental Medicine and The Children's Hospital of Philadelphia teamed up to investigate the underlying reasons for these impairments. They found that commonly used antiretroviral medications (protease inhibitors Ritonavir and Lopinavir) disrupted the differentiation of oligodendrocytes, crucial brain cells that manufacture myelin, the fatty material that serves to insulate neurons, helping them transmit signals in the brain fast and efficiently.

This disruption, the researchers said, may be responsible for some of the cognitive problems that HIV patients experience, and point to a need for rethinking how HIV drugs are designed and prescribed, particularly for children on ART, in whom myelin is still forming at high rates.

"Pharmaceutical companies have done an amazing job developing drugs to make HIV patients live longer, but we're not done," said Kelly L. Jordan-Sciutto, professor and chair of Penn Dental Medicine's Department of Pathology, who co-led the research with Judith B. Grinspan, a research scientist at CHOP and professor of neurology at Penn's Perelman School of Medicine. "The message we want to get out there is that we want to make these patients' lives better while they are on ART."

The research was published this November in the Journal of Neuropathology and Experimental Neurology.

The researchers have yet to determine a mechanism by which myelin protein levels are altered with ART, but are investigating a number of avenues. They are also evaluating how different HIV medications can affect oligodendrocyte and myelin formation, as the recommended drug cocktails frequently change.

The implications of these findings may be particularly important for pediatric patients, some of whom may have been on ART from birth. Since HIV-infected children exhibit higher rates of neurocognitive disorders such as seizures, depression, and ADHD, the researchers stress that a revised look at treatments for pediatric patients may be warranted, or an additional therapy to prevent the white matter loss in both adults and children could be developed to go hand in hand with the ART.

Contact:
Beth Adams
215-573-8224
adamsnb@upenn.edu


'/>"/>
SOURCE Penn Dental Medicine
Copyright©2016 PR Newswire.
All rights reserved


Related medicine technology :

1. Abaxis, Inc. to Present at the Stifel Annual Dental & Veterinary Conference
2. Heska Corporation to Present at the Stifel Dental & Veterinary Conference
3. Stanley Bergman Delivers Commencement Address At Stony Brook School Of Dental Medicine
4. Umbie DentalCare - Multiple Opportunities One Solutions
5. GRW bearing lubrication tests yield maximum wear life for medical and dental instruments
6. SmileBest Dental & Orthodontics Opens Their First Office in Hurst, Texas
7. Henry Schein Dental And American Dental Hygienists Association Host "Dream Center" To Mark 100th Anniversary Of Profession
8. TopProdeals.com Rises to Top as Discount Dental Supply Leader
9. Global Dental Restorative Supplies Industry
10. Global Dental Orthodontic Supplies Industry
11. Henry Schein Chairman Of The Board & CEO Receives Centennial Recognition Award For Extraordinary Commitment To The National Dental Association
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/17/2019)... (PRWEB) , ... July 17, 2019 , ... The American ... APNA Board of Directors and 2020 Nominating Committee . Elected by psychiatric-mental health nurse ... APNA 33rd Annual Conference in New Orleans, LA, October 2-5, 2019. , ...
(Date:7/17/2019)... ... July 17, 2019 , ... ... solution needed to attract new customers, better engage existing patients and collaborate with ... digital marketing services in tandem with an all-in-one platform. With the Updox approach, ...
(Date:7/17/2019)... LOS ANGELES (PRWEB) , ... July 17, 2019 , ... ... Angeles to reclaim their smiles with Kanani's innovated bonding procedures. Bonding is just one ... other methods, bonding can be done in a single visit, and patients leave immediately ...
Breaking Medicine Technology:
(Date:7/17/2019)... SAN DIEGO (PRWEB) , ... July 17, 2019 , ... ... not become parents. Every Intended Parents’ story differs , but, in addition to ... their Surrogate. , Across the globe, more and more Intended Parents are electing to ...
(Date:7/17/2019)... ... July 17, 2019 , ... Dr. Jonathan Zaidan, MD, FACOG, President ... WJR’s Health Woman Show. The show airs on Wednesday, July 17ths at 7pm. ... , Dr. Zaidan and co-host Ann Thomas discuss the challenges that women face when ...
(Date:7/13/2019)... , ... July 12, 2019 , ... ... YCBD), has been named a “Brand to Watch” by Brightfield Group, a leading ... cbdMD in the top 10 of domestic CBD companies in two categories, Topicals ...
(Date:7/11/2019)... ... 2019 , ... Swagelok Southeast Texas, a distributor for Ohio-based ... acquisition of another Houston-area distributor. The acquisition of the Swagelok Central Houston facility ... Nederland and Houston. , With this expansion, Swagelok Southeast Texas also extends ...
(Date:7/10/2019)... ... 10, 2019 , ... HMP, a leader in healthcare events and education, today ... Pathways Congress, taking place October 11-13, 2019 in Boston. , Launched in 2016, the ... the expansion of clinical pathways as a decision support tool and their increasing influence ...
Breaking Medicine News(10 mins):